T. Powles Et Al. , "Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial," LANCET ONCOLOGY , vol.22, no.7, pp.931-945, 2021
Powles, T. Et Al. 2021. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. LANCET ONCOLOGY , vol.22, no.7 , 931-945.
Powles, T., Csoszi, T., ÖZGÜROĞLU, M., Matsubara, N., Geczi, L., Cheng, S. Y., ... Fradet, Y.(2021). Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. LANCET ONCOLOGY , vol.22, no.7, 931-945.
Powles, Thomas Et Al. "Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial," LANCET ONCOLOGY , vol.22, no.7, 931-945, 2021
Powles, Thomas Et Al. "Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial." LANCET ONCOLOGY , vol.22, no.7, pp.931-945, 2021
Powles, T. Et Al. (2021) . "Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial." LANCET ONCOLOGY , vol.22, no.7, pp.931-945.
@article{article, author={Thomas Powles Et Al. }, title={Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial}, journal={LANCET ONCOLOGY}, year=2021, pages={931-945} }